{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT02652130",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "OutcomeMeasureParamType",
                  "OutcomeMeasurePopulationDescription",
                  "OutcomeMeasureReportingStatus",
                  "OutcomeMeasureTimeFrame",
                  "OutcomeMeasureTitle",
                  "OutcomeMeasureType",
                  "OutcomeMeasureTypeUnitsAnalyzed",
                  "OutcomeMeasureUnitOfMeasure",
                  "OutcomeMeasurementComment",
                  "OutcomeMeasurementGroupId",
                  "OutcomeMeasurementLowerLimit",
                  "OutcomeMeasurementSpread",
                  "OutcomeMeasurementUpperLimit",
                  "OutcomeMeasurementValue",
                  "OverallOfficialAffiliation",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OutcomeMeasureParamType": [
                              "Number",
                              "Number"
                        ],
                        "OutcomeMeasurePopulationDescription": [
                              "Safety population included all participants who signed the informed consent form and received at least one dose of study treatment (complete or partial) in the study MSB-GVHD001 and who signed the informed consent form for the study MSB-GVHD002 were followed across both the studies MSB-GVHD001 and MSB-GVHD002.",
                              "Duration of Response population included all participants who participated in Study MSB-GVHD001 and showed OR or very good partial response (VGPR) to remestemcel-L at Day 28 in Study MSB-GVHD001. The OS was evaluated across both Studies MSB-GVHD001 and MSB-GVHD002."
                        ],
                        "OutcomeMeasureReportingStatus": [
                              "Posted",
                              "Posted"
                        ],
                        "OutcomeMeasureTimeFrame": [
                              "From Baseline Day 1 in the Study MSB-GVHD001 up to Day 180 in Study MSB-GVHD002 (180 days)",
                              "From Baseline (Day 1) in the Study MSB-GVHD001 up to Day 180 in the Study MSB-GVHD002 (180 days)"
                        ],
                        "OutcomeMeasureTitle": [
                              "Overall Survival Rate Through Day 180",
                              "Overall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD001"
                        ],
                        "OutcomeMeasureType": [
                              "Primary",
                              "Secondary"
                        ],
                        "OutcomeMeasureTypeUnitsAnalyzed": [],
                        "OutcomeMeasureUnitOfMeasure": [
                              "percentage of participants",
                              "percentage of participants"
                        ],
                        "OutcomeMeasurementComment": [],
                        "OutcomeMeasurementGroupId": [
                              "OG000",
                              "OG000"
                        ],
                        "OutcomeMeasurementLowerLimit": [],
                        "OutcomeMeasurementSpread": [],
                        "OutcomeMeasurementUpperLimit": [],
                        "OutcomeMeasurementValue": [
                              "68.5",
                              "78.9"
                        ],
                        "OverallOfficialAffiliation": [
                              "Mesoblast, Inc."
                        ],
                        "NCTId": [
                              "NCT02652130"
                        ]
                  }
            ]
      }
}